drugset
Drugs / CAPVAXIVE™
last change Aug 2026 re-read 3 minutes ago

CAPVAXIVE™

Investigated by
Merck Sharp & Dohme LLC

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved EU (EMA) Capvaxive — 2025-03-24 europa.eu ↗

Trials 1

today
EU approved 2025
NCT07712575 · Ph 1
202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07712575 Aug 2026 → Jun 2028 expected — Merck Sharp & Dohme LLC Not yet recruiting No outcome recorded

Press releases naming this drug 9 releases

DateIssuerRelease
2026-06-18 Merck Sharp & Dohme LLC U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease merck.com ↗
2025-10-21 Merck Sharp & Dohme LLC Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in U.S. Adults merck.com ↗
2025-09-11 Merck Sharp & Dohme LLC CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease merck.com ↗
2025-03-26 Merck Sharp & Dohme LLC European Commission (EC) Approves Merck’s CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults merck.com ↗
2025-01-31 Merck Sharp & Dohme LLC Merck Receives Positive EU CHMP Opinion for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults merck.com ↗
2024-10-23 Merck Sharp & Dohme LLC CDC’S ACIP Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and Older merck.com ↗
2024-10-16 Merck Sharp & Dohme LLC Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease merck.com ↗
2024-06-27 Merck Sharp & Dohme LLC CDC’S ACIP Unanimously Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults merck.com ↗
2024-06-17 Merck Sharp & Dohme LLC U.S. FDA Approves CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults merck.com ↗

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CAPVAXIVE ClinicalTrials.gov intervention name — accepted as the source's own label NCT07712575 ↗